Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Blue Horizon International
NEW YORK, May 6, 2014 /PRNewswire/ -- Brian Mehling, M.D., an American orthopedic trauma surgeon and founder of Blue Horizon International, was awarded a temporary license to practice medicine in Nigeria. Dr. Mehling, a researcher and philanthropist, is spearheading groundbreaking research in stem cell therapy focused on the health benefits of cell therapy in treating and managing diseases.
Blue Horizon International is a healthcare consulting company with a unique concept that combines treatment, research, and philanthropic efforts. Blue Horizon International provides the highest quality care available in surgical and medical treatments globally, the most advanced technologies in stem cell therapies, and also provides resources needed to assist children and adults who are medically underserved. Blue Horizon Stem Cell is a division of Blue Horizon International that provides stem cell therapy and research to achieve health benefits. The program is associated with The Stem Cell Centre, Hongqiao Brain Hospital and Wuhan University School of Basic Medical Science, Wuhan, China.
Dr. Mehling started his path in medicine through undergraduate study at Harvard University, obtaining his Bachelor of Arts and Master of Science degrees in Biochemistry from Ohio State University.
After completing his degree in medicine at Wright State University School of Medicine, Dr. Mehling received his post graduate education through residencies and fellowships at St. Joseph's Hospital in Paterson, NJ and the Graduate Hospital in Philadelphia, PA, while pursuing a Ph.D. in Chemistry.
An orthopedic trauma surgeon, Dr. Mehling operates his own practice, Mehling Orthopedics, in both West Islip, NY and Hackensack, NJ. He is also has privileges at Good Samaritan Hospital, Hackensack University Medical Center, Hackensack University Medical Center at Pascack Valley, St. Joseph's Medical Center, and St. Joseph's Wayne Medical Center.
Dr. Mehling has traveled extensively throughout Asia and the Middle East observing firsthand the differences in healthcare standards. Identifying the need for a universally high quality standard, he founded Blue Horizon International.
He and his colleagues have successfully treated and monitored more than 600 patients using stem cell and regenerative therapies. Patients have been treated for a wide range of diseases and disorders including spinal cord injury and cerebral palsy.
Dr. Mehling founded the Blue Horizon Charitable Foundation to enhance the quality of health to those in need. Efforts are focused on helping human service and health organizations, while also providing resources benefiting children orphaned from war and disease.
Apart from his professional organizations, Dr. Mehling personally contributes his time and resources to charitable causes. He has sponsored patients' trips to China for stem cell treatments, as well as hosting charitable events from his own homes in New York, the Hamptons, and France. Notable beneficiaries include The Sean Kimmerling Testicular Cancer Foundation and the Children of Chernobyl.
Dr. Mehling also raises awareness through his film company, Industrial Motion Pictures (IMP). His full feature documentary, "Tiny Tears," presented at the Cannes and New York Film Festivals, is a collection of testimonials from caregivers and volunteers in different countries, devoted to saving and helping children affected by AIDS. He is currently working on several other film projects, among them a documentary exploring the future of medicine and revolution taking place in stem cell and regenerative therapies.
Uniquely positioned to take advantage of its clinical research, BHI has safely and efficiently performed more than 2,600 procedures, documenting each one while tracking the progress of patients throughout their treatment cycle and follow up. BHI's stem cell therapy program is associated with The Stem Cell Centre, Hongqiao Brain Hospital and Wuhan University School of Basic Medical Science, Wuhan, China and Medissimo Hospital, Bratislava, Slovakia (orthopedic therapies only).
"We are focused on bringing advanced stem cell therapies within reach of a wider audience because we envision a future in which stem cell treatments are preferred over many surgical, pharmacological, and rehabilitative medical services," added Dr. Mehling
Stem cell treatments and therapies also show great promise in the management and treatment of diabetes (Types l and ll), cardiovascular disorders, arthritis, autoimmune disorders, spinal cord injuries, multiple sclerosis, brain trauma, sports trauma, and anti-aging.
BHSC stem cell treatments are safe, effective, and ethically derived from non-embryonic stem cell research. The BHSC stem cell laboratories have international ISO and GMP accreditations, which illustrates a commitment to high quality care and patient safety.
Blue Horizon Stem Cell is a division of Blue Horizon International that provides stem cell therapy and research to achieve health benefits. For more information, visit www.bluehorizonstemcells.com.
PRLog ID: www.prlog.org/12319168
©2012 PR Newswire. All Rights Reserved.